Elevation of serum ferritin levels as a marker for active systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 15, Issue 1, 1997, Pages 39-44

  Nishiya, K ^a   Hashimoto, K ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

acute phase proteins; autoimmune disease; C reactive protein; serum ferritin

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FERRITIN; GOLD; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FERRITINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 0030933079     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. WOODS VL JR, ZVAIFLER NJ: Pathogenesis of systemic lupus erythematosus. In: KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology, 3rd ed, Vol. 2., Philadelphia, W.B. Saunders Inc, 1989; 1077-100.
2. BLACKBURN WD: Validity of acute phase proteins as markers of disease activity. J Rheumatol 1994; 21 (suppl 42): 9-13.
3. BAUMANN H, GAULDIE J: The acute phase response. Immunul Today 1994; 15: 74-80.
4. MACFARLANE CM: C-reactive protein. Properties and biological action with particular reference to systemic lupus erythematosus. S Afr Med J 1985; 67: 890-2.
5. TERBORG EJ, HORST G, LIMBURG PC, VANRIJSWIJK MH, KALLENBERG CGM: C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990; 17: 1642-8.
6. KUSHNER I: C-reactive protein in rheumatology. Arthritis Rheum 1991; 34: 1065-8.
7. AMOS RS, CONSTABLE TJ, CROCKSON RA, CROCKSON AP, MCCONKEY B: Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977; 1: 195-7.
8. DIXON JS, BIRD HA, SITTON NG, PICKUP ME, WRIGHT V: C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 1984; 13: 39-44.
9. JACOBS A, WORWOOD M: Ferritin in serum: Clinical and biochemical implications. N Engl J Med 1975; 292: 951-6.
10. BIRGEGARD G, HALLGREN R, KILLANDER A, STROMBERG A, VENGE P, WIDE L: Serum ferritin during infection. A longitudinal study. Scand J Haematol 1978; 21: 333-40.
11. ROTHWELL RS, DAVIS P: Relationship between serum ferritin, anemia, and disease activity in acute and chronic rheumatoid arthritis. Rheumatol Int 1981; 1: 65-7.
12. BLAKE DR, BACON PA: Serum ferritin and rheumatoid disease. Br Med J 1981; 282: 1273-4.
13. NISHIYA K, MATSUEDA H, SHIRAKAMI T, HATANO M, YANO K, OGURA T, TAKAOKA M, HIRAKI Y, AONO K, EZAWA H, OTA Z: Serum and urinary ferritin levels in patients with rheumatoid arthritis. Acta Med Okayama 1985; 39: 321-8.
14. PORTER DR, STURROCK RD, CAPELL HA: The use of serum ferritin estimation in the investigation of anaemia in patients with rheumatoid arthritis. Clin Exp Rheumatol 1994; 12: 179-82.
15. OTA T, HIGASHI S, SUZUKI H, ETO S: Increased serum ferritin levels in adult Still's disease. Lancet 1987; i: 562-3.
16. SCHWARZ-EYWILL M, HEILIG B, BAUER H, BREITBART A, PEZZUTTO A: Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis 1992; 51: 683-5.
17. VAN-REETH C, MOEL GL, LASNE Y, REVENANT MC, AGNERAY J, KAHN MF, BOURGEOIS P: Serum ferritin and isoferritins are tools for diagnosis of active adult Still's disease. J Rheumatol 1994; 21: 890-5.
18. TAN EM, COHEN AS, FRIES JF, MASI AT, MCSHANE DJ, ROTHFIELD NF, SCHALLER JG, TALAL N, WINCHESTER RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
19. ARNETT FC, EDWORTHY SM, BLOCH DA, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
20. GLADMAN DE, KEYSTONE E, UROWITZ M, CANE D, POPLONSKI L: Impaired antigen-specific suppressor cell activity in patients with systemic lupus erythematosus. Clin Exp Immunol 1980; 40: 77-82.
21. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH, and the COMMITTEE ON PROGNOSIS STUDIES IN SLE: Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
22. BANKS RE, FORBES MA, STORR M, HIGGINSON J, THOMPSON D, RAYNES J, ILLINGWORTH JM, PERREN TJ, SELBY PJ, WHICHER JT: The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995; 102: 217-23.
23. KONIJN AM, HERSHKO C: Ferritin synthesis in inflammation. I. Pathogenesis of impaired iron release. Br J Haematol 1977; 37: 7-16.
24. BLAKE DR, BACON PA, EASTHAM EJ, BRIGHAM K: Synovial fluid ferritin in rheumatoid arthritis. Br Med J 1980; 281: 715-6.
25. MUIRDEN KD: Ferritin in synovial cells in patients with rheumatoid arthritis. Ann Rheum Dis 1966; 25: 387-401.
26. NISHIYA K, KAWABATA F, OTA Z : Elevated urinary ferritin in lupus nephritis. J Rheumatol 1989; 16: 1513-4.
27. KLOCKARS M, WEBER T, TANNER P, HELLSTROM PE, PETTERSSON T: Pleural fluid ferritin concentrations in human disease. J Clin Pathol 1985; 38: 818-24.
28. DARLINGTON GJ, WILSON DR, LACHMANN LB: Monocyte conditioned medium, interleukin 1 and tumor necrosis factor stimulate the acute phase response in human hepatoma cell lines in vitro. J Cell Biol 1986; 103: 787-93.
29. GAULDIE J, RICHARDS C, HAMISH D, LANDSDORP P, BAUMANN H: Interferon beta 2/B cell stimulatory factor type-2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251-5.
30. ROSE TM, BRUCE AG: Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin-6. Proc Natl Acad Sci USA 1991; 88: 8641-5.
31. BAUMANN H, SCHENDEL P: Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem 1991; 266: 20424-7.
32. LINKER-ISRAELI M, BAKKE AC, KITRIDOU RC, GENDLER S, GILLIS S, HORWITZ DA: Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 2651-5.
33. ROGERS JT, BRIDGES KR, DURMOWICZ GP, GLASS J, AURON PE, MUNRO HN: Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990; 265: 14572-8.
34. HIRAYAMA M, KOHGO Y, KONDO H, SHINTANI N, FUJIKAWA K, SASAKI K, KATO J, NIITSU Y: Regulation of iron metabolism in HepG2 cells: a possible role for cytokines in the hepatic deposition of iron. Hepatology 1993; 18: 874-80.
35. MAURY CPJ, TEPPO AM: Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146-50.
36. SPRONK PE, TERBORG EJ, LIMBURG PC, KALLENBERG CGM: Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol 1992; 90: 106-10.
37. HIGASHI S, OTA T, ETO S : Biochemical analysis of ferritin subunits in sera from adult Still's disease patients. Rheumatol Int 1995; 15: 45-50.
38. MORTENSEN RF, OSMAND AP, GEWURZ H: Effects of C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med 1975; 141: 821-39.
39. MÜLLER H, FEHR J: Binding of C-reactive protein to human polymorphonuclear leukocytes: evidence for association of binding sites with Fc receptors. J Immunol 1986; 136: 2202-7.
40. JIANG H, ROBEY FA, GEWURZ H: Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med 1992; 175: 1373-9.
41. SZALAI AJ, BRILESDE, VOLANAKIS JE: Human C-reactive protein is protective against fatal streptococcus pneumoniae infection in transgenic mice. J Immunol 1995; 155: 2557-63.
42. FRANK MM, HAMBURGER MI, LAWLEY TJ, KIMBERLY RP, PLOTZ PH: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1979; 300: 518-23.
43. MATZNER Y, HERSHKO C, POLLIACK A, KONIJN AM, IZAK G: Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol 1979; 42: 345-53.
44. BIEMOND P, SWAAK AJG, VANEIJK HG, KOSTER JF: Intraarticular ferritin-bound iron in rheumatoid arthritis. Arthritis Rheum 1986; 29: 1187-93.
45. HARADA T, BABA M, TORII I, MORIKAWA S: Ferritin selectively suppresses delayed-type hypersensitivity responses at induction or effector phase. Cell Immunol 1987; 109: 75-88.
46. MORIKAWA K, OSEKO F, MORIKAWA S: H-and L-rich ferritins suppress antibody production, but not proliferation, of human B lymphocytes in vitro. Blood 1994; 83: 737-43.
47. HANN HWL, STAHLHUT MW, LEE S, LONDON WT, HANN RS: Effects of isoferritins on human granulocytes. Cancer 1989; 63: 2492-6.
48. BROXMEYER HE, BOGNACKI J, DÖRNER MH, DE SOUSA M: Identification of leukemia-associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages. J Exp Med 1981; 153: 1426-44.